What is New In Our Community
Get access to our breaking news, company information, publications, and resources
Press Releases
Pillar Biosciences oncoReveal™ CDx pan-cancer solid tumor IVD now FDA approved for general tumor profiling on the Illumina MiSeq™Dx System
April 23, 2024
No Comments
Company continues to execute on its global strategy to bring highly accurate and sensitive NGS cancer diagnostics to enable localized testing Natick, MA – April
Pillar Biosciences to Present at NYBIO | NYSE Life Science Company Showcase on December 14th
December 7, 2023
No Comments
Natick, MA – December 7, 2023 – Pillar Biosciences is pleased to announce that Randy Pritchard, Chief Executive Officer, and Vincent Ricci, Chief Financial Officer,
Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting
November 8, 2023
No Comments
NATICK, Mass. – November 8, 2023 – (PR NEWSWIRE) – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators
Resources
2023
2022
2021
2020
2019
Earlier Presentations
2023
2022
2021
2020
2019
Earlier Presentations
2024
2023
2022
2021
2020
2019
2018
Earlier Posters
2024
2023
2022
2021
2020
2019
2018
Earlier Posters
2024
2023
2022
2021
2019
2018
Earlier Publications
2024
2023
May 05, 2023
Minimizing Sample Failure Rates for Challenging Clinical Tumor Samples
Learn more2022
August 08, 2022
Quality metrics for enhanced performance of an NGS panel using single-vial amplification technology
Learn moreNovember 03, 2022
Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?
Learn more
February 01, 2022
Abnormal TP53 Predicts Risk of Progression in Patients With Barrett’s Esophagus Regardless of a Diagnosis of Dysplasia
Learn more
June 17, 2022
Localizing next-generation sequencing testing for cancer patients
Learn more2021
Sept 30, 2021
Effective and Accurate CNV Calling Using the PiVAt Bioinformatics Platform
Learn More
2019
Jan 05, 2019
Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients
Learn More
2018
Aug 28, 2018
Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing
Learn More
Earlier Publications
Jul 12, 2017
Amplification of overlapping DNA amplicons in a single-tube multiplex PCR for targeted next-generation sequencing of BRCA1 and BRCA2
Learn More
Apr 06, 2017
Feasibility Study of Molecular Profiling of Gastric Cancer Specimens From Rwanda
Learn More
Pillar Biosciences Inc.
9 Strathmore Rd., Natick MA, 01760